Marquis Top Doctors

Dr. Robert Hardi

Title: Gastroenterologist
Company: Chevy Chase Gastroenterology
Location: Bethesda, Maryland, United States

Robert Hardi, Gastroenterologist at Chevy Chase Gastroenterology, has been recognized by Marquis Who’s Who Top Doctors for dedication, achievements, and leadership in gastroenterology practice, research and education.

Hailing from Hungary, Dr. Hardi obtained a Medical Doctor, summa cum laude, from Semmelweis University Medical School in Budapest in 1972. He then served a postdoctoral fellowship with Roswell Park Memorial Institute in Buffalo, New York with postgraduate training in biochemistry and genetics. He then underwent clinical training in Hanover Medical School in Germany and additional training in Budapest, as well as clinical fellowship training in hematology and oncology with the University of New Mexico in Albuquerque, followed by clinical fellowship training in gastroenterology, Cornell University Medical School, now known as Weill Cornell Medical College. Dr. Hardi is board certified in internal medicine and gastroenterology and is a certified clinical investigator.

For many years, Dr. Hardi provided superior care in his private practice and then as part of the Metropolitan Gastroenterology Group and Capital Digestive Care in Washington, where he specialized in general gastroenterology, inflammatory bowel diseases, colon cancer screenings and irritable bowel syndrome. He has notably served as a principal investigator for over 350 gastroenterology clinical trials. Due to his interest in inflammatory bowel disease, Dr. Hardi also served three years as a national board member of the Crohn’s and Colitis Foundation of America and served as the medical director and principal investigator of Chevy Chase Clinical Research between 1996 and 2018, as well as three years as a national board member of the Crohn’s and Colitis Foundation of America.

Dr. Hardi is also a renowned educator in the gastroenterology field, initially teaching as an assistant professor of genetics at Eotvos University of Science in Budapest. He later became a clinical associate professor of medicine at George Washington University Medical School and clinical assistant professor at Georgetown University Medical School. Since 2020, he has excelled as director of clinical development with Altimmune, Inc. in Gaithersburg, Maryland, senior clinical scientist with Medipredict and as medical director with Capitol Research from 2018 to 2020. Dr. Hardi’s professional memberships include a fellowship in the American Gastroenterological Association and as a board member and past president of the Academy of Physicians in Clinical Research. He has received various awards from the National Board of the Crohn’s and Colitis Foundation of America, was a listee in Best Doctors of Washington in Washingtonian Magazine and a multiple-time listee in Best Gastrointestinal Doctors of America.

According to Dr. Hardi, what made him successful was his persistence, hard work, ability to pay attention to detail and the fact that he loved what he did. He enjoyed taking care of his patients and doing clinical research. He became involved in his profession as a result of his basic science training and involvement in hepatology, which includes biochemistry and those subspecialties of integrative medicine that also combine the instant gratification of a surgeon by performing a procedure or surgery. In the coming years, he intends to continue serving his patients and is looking forward to seeing the successes of the two companies (Medipredict and Altimmune, Inc.) with which he is involved.

For more information, please visit:
Press Release 

Contact Dr. Hardi:

Share with:


More to explore

Veronica Vlad

Title: Senior Director of Hematology, Oncology, and Global Project Management Company:  Thermo Fisher Scientific, Inc. Location: Spring, Texas, United States Veronica

Sachidanand “Peter” R. Peteru

Title: Director of Consultation and Liaison Psychiatry Company: Jamaica Hospital Medical Center Location: Jamaica, New York, United States Sachidanand “Peter” R.